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Available online 16 June 2016Background: Myocardial ischemia is associated with alterations in cardiac metabolism, resulting in decreased
fatty acid oxidation and increased lipid accumulation. Here we investigate howmyocardial lipid content and dy-
namics affect the function of the ischemic heart, and focus on the role of the lipid droplet protein perilipin 5
(Plin5) in the pathophysiology of myocardial ischemia.
Methods and results:We generated Plin5−/−mice and found that Plin5 deﬁciency dramatically reduced the tri-
glyceride content in the heart. Under normal conditions, Plin5−/−micemaintained a close to normal heart func-
tion by decreasing fatty acid uptake and increasing glucose uptake, thus preserving the energy balance. However,
during stress or myocardial ischemia, Plin5 deﬁciency resulted in myocardial reduced substrate availability, se-
verely reduced heart function and increased mortality. Importantly, analysis of a human cohort with suspected
coronary artery disease showed that a common noncoding polymorphism, rs884164, decreases the cardiac ex-
pression of PLIN5 and is associated with reduced heart function following myocardial ischemia, indicating a
role for Plin5 in cardiac dysfunction.
Conclusion: Our ﬁndings indicate that Plin5 deﬁciency alters cardiac lipid metabolism and associates with re-
duced survival followingmyocardial ischemia, suggesting that Plin5 plays a beneﬁcial role in the heart following
ischemia.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Perilipin 51. Introduction
Myocardial ischemia and ischemic heart disease are among themain
causes of mortality worldwide. In the search for novel treatment strate-
gies to improve cardiac function and outcome in patients with ischemic
heart disease, researchers have extensively investigated metabolichlgrenska University Hospital,
land Ltd. This is an open access articlabnormalities of the failing ischemic heart [1]. These abnormalities are
characterized by reduced energy-efﬁcient lipid oxidation [2,3], in-
creased accumulation of myocardial lipids [4–6] and enhanced utiliza-
tion of glucose for energy production [7–9]. It is unclear how
myocardial lipid content and dynamics affect the function of the failing
ischemic heart, but the balance between lipid utilization and storage
appears to be crucial [10,11].
Myocardial lipids are stored in cytosolic droplets. These highly
dynamic organelles consist of a core of neutral lipids surrounded by a
complex surface containing numerous proteins of importance for the
formation, stability, and trafﬁcking of lipid droplets in the cell [12]. Ine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cellular energy dynamics (e.g., in mediating the recruitment of
mitochondria to lipid droplets during conditions of high substrate avail-
ability) [13,14]. The lipid droplet protein perilipin 5 (Plin5), which is
highly expressed in the heart and other oxidative tissues [15,16], has
attracted interest because of its potential role in cardiac function. Plin5
stabilizes lipid droplets and may facilitate the association between
lipid droplets and mitochondria [14]. However, in vivo studies of Plin5
deﬁciency have so far been elusive, revealing only minor effects on
heart function [16–18]. It remains to be determined whether Plin5
plays a key role for pathophysiology of myocardial ischemia.
Here, we used Plin5−/−mice to investigate the role of Plin5 in myo-
cardial lipid dynamics, cardiac function, and outcome after myocardial
ischemia. We found that Plin5 deﬁciency resulted in reduced cardiac
lipid content, increased glucose uptake and was associated with a
poorer outcome after myocardial ischemia. Furthermore, genetic
variation of PLIN5 in humans was associated with impaired cardiac
function after myocardial ischemia.2. Methods
2.1. Mice
Plin5−/−mice were generated in compliance with the guidelines of
the Animal Care and Use Committee of the National Institutes of Health
under a Division of Intramural Research, National Institute of Diabetes
and Digestive and Kidney Diseases–approved animal study protocol.
Plin5−/−mice were generated (Fig. S1) as described in the Supplemen-
tal information section. All animal studies were approved by the local
animal ethics committee and conform to the guidelines from Directive
2010/63/EU of the European Parliament on the protection of animals
used for scientiﬁc purposes. At the end of experiments, mice were
sacriﬁced using 5% isoﬂurane and cervical dislocation.2.2. Immunoblotting
Brieﬂy, frozen mouse heart tissue was homogenized and proteins
were extracted with the Qproteosome Mammalian Protein Prep Kit
(Qiagen, Hilden, Germany). Speciﬁc antibodies for Plin5 (GP31) and
Na,K-ATPase (ab7671) (Abcam) were used. More detailed information
can be found in the Supplemental information section.2.3. Lipid analyses of heart muscle
Heart tissuewas excised from fedwildtype (WT) and Plin5−/−mice,
and 50–100mg of tissue was used for lipid analyses, as described in the
Supplemental information section.2.4. Electron microscopy of mouse hearts
Hearts were harvested from fasted mice and prepared as described
in the Supplemental information section.2.5. GC–MS and MS/MS spectroscopy
Succinate and lactate from pulverized heart tissue (about
50 mg) were extracted using 1 ml of diethylether. 100 μl of the
ether fraction was then mixed with 100 μl of N-methyl-N-tert-
butyldimethylsilyltriﬂuoroacetamide (MTBSTFA, Sigma) and incubated
at 70 °C for 1 h. The derivatized samplewas then analyzed usingGC–MS.
The separation was done on a 60 m DB-5MS column and the detection
was made in SIM mode. Extraction and analysis (HPLC-MS/MS) of
acetylCoA were done as previously described [19].2.6. mRNA expression in heart tissue from mice
Total RNA was extracted from snap-frozen mouse heart tissue
with the RNeasy Fibrous Tissue Kit (Qiagen). cDNA was synthesized
with the high-capacity cDNA Reverse Transcription Kit (Applied
Biosystems) and random primers. mRNA expression of genes of interest
was analyzed with TaqMan real-time PCR in an ABI Prism 7900 HT
Detection System (Applied Biosystems). The TaqMan Gene Expression
assays used were mm01135198_m1 (for CD36), mm00449511_m1
(fatty acid transfer protein), mm00434764_m1 (lipoprotein lipase),
mm00440939_m1 (peroxosome proliferator-activated receptor α),
mm01208835_m1 (peroxisome proliferator-activated receptor gamma
coactivator 1α), mm004872206_m1 (carnitine palmitoyltransferase
1b), andmm00431611_m1 (median-chain acyl-coenzyme A dehydroge-
nase) (all from Applied Biosystems). HPRT (Applied Biosystems) was
used as an internal control.
2.7. In vivo [3H] palmitate uptake and incorporation into triglycerides,
diglycerides and phospholipids
After a 5-h fast, mice were anesthetized with N-isoﬂurane
and injected retroorbitally with [3H]-palmitate (5 μCi; Amersham
Biosciences) complexed with 6% bovine serum albumin in phosphate-
buffered saline (PBS). Blood was taken from the tail 2 min after the
injection. Mice were perfused with PBS 30 min after the injection. The
heart was harvested, rinsed in PBS to remove all blood, and snap frozen
in liquid nitrogen. Frozen tissue was pulverized into a ﬁne powder and
analyzed as described in the Supplemental information section.
2.8. In vivo glucose uptake
In vivo glucose uptake was measured as described [20], with some
modiﬁcations. Brieﬂy, after a 4-h fast, mice received an intraperitoneal
injection of saline containing 50 Ci/kg 2-deoxy-D-[3H]-glucose (speciﬁc
activity, 9.0 Ci/mmol; AmershamBiosciences). Bloodwas collected after
5 min and 60 min. After 60 min, the heart was excised, snap-frozen in
liquid nitrogen, and homogenized in ice-cold buffer 50 mM Tris–HCl
(pH 7.4) and 250 mM sucrose. Radioactivity was counted in blood and
homogenates.
2.9. Bioluminescence imaging of glycogen
Sections of snap-frozen infarcted and control hearts from WT and
Plin5−/−mice were cut in 16-μm-thick sections, ﬁxed on cover glasses,
and heat-inactivated at 95 °C for 10 min. Bioluminescence imaging of
glycogen was performed as described in the Supplemental information
section.
2.10. Induction of myocardial infarction
Before induction of myocardial infarction, the mice were anesthe-
tized with isoﬂurane, orally intubated, and connected to a small-
animal ventilator (SAR-830, Geneq, Montreal, Canada) distributing a
mixture of oxygen, air and 2–3% isoﬂurane. ECG electrodes were placed
on the extremities, and cardiac rhythm was monitored during surgery.
An incision was made between the 4th and 5th ribs to reveal the
upper part of the anterior LV wall and the lower part of the left atrium.
Myocardial infarction was induced by ligating the left anterior descend-
ing coronary artery immediately after the bifurcation of the left
coronary artery. The efﬁcacy of the procedure was immediately veriﬁed
by characteristic ECG changes, and akinesis of the LV anteriorwall. After
veriﬁcation of the infarction, the lungswere hyperinﬂated, positive end-
expiratory pressure was applied, and the chest was closed. The mice
received an intraperitoneal injection of 0.1 ml Temgesic to relieve post-
operative pain and were allowed to recover spontaneously after
isoﬂurane administration was stopped.
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Mice were anesthetized with N-isoﬂuorane (1.2%) and underwent a
baseline echocardiographic examination with a VEVO 770 system
(VisualSonics, Ontario, Canada), as further described in the Supplemen-
tal information section.
2.12. Dobutamine stress analysis
The mice were injected intraperitoneally with dobutamine
(2 μg/g body weight) and echocardiography was performed. Mice
were excluded from the study if their heart rate did not increase by
N100 beats/min.
2.13. Human subjects
The Coronary Flow Reserve and Cardiovascular Events (CEVENT)
study consists of 468 patients with clinically suspected coronary artery
disease recruited at the Department of Clinical Physiology, Sahlgrenska
University Hospital, Gothenburg, Sweden, from 2006 to 2008. Patient
characteristics are presented in Table S1. The study was conducted in
accordance with the Declaration of Helsinki. All participants gave
written informed consent, and the study was approved by the local
ethics committee in Gothenburg.
2.14. Myocardial perfusion scintigraphy
All patients underwent myocardial perfusion scintigraphy to detect
coronary artery disease. A 2-day nongated stress/gated rest test was
performed with the 99 mTc-sestamibi protocol. Patients underwent a
symptom-limited ergometry test, maximal exercise, or pharmacological
testing with adenosine or dobutamine. Images were acquired with a
dual-head SPECT camera (Inﬁnia or Millenium VG, General Electric).
Automatically generated information on myocardial ischemia and
infarction [21] was interpreted by one experienced physician. Wall
motion scores were calculated as the sum of wall motion abnormalities
in a 17-segment model. The patients were grouped according to the
absence or presence of left ventricle perfusion defects (clinical score)
or wall motion abnormalities.
2.15. Selection of SNPs, genotyping, and expression analysis
The PLIN5 SNPs we investigatedwere selected based on an expected
minor allele frequency N5%, no or weak linkage disequilibrium, and
presumed potential effects on protein function (mediated by amino
acid change) and protein concentration (mediated by mRNA stability
and splicing pattern). Genomic DNA was isolated from whole blood by
standard protocols. Four SNPs in PLIN5 (rs11085080G, rs11610090,
rs1062223, rs884164) were successfully genotyped in 466 of 468 pa-
tients (DNA was unavailable from 2 patients) with TaqMan technology
(Applied Biosystems, Foster City, CA) (Table S2). Human heart biopsies
were obtained from patients undergoing valve surgery, and mRNA ex-
pression according to genotype was assessed as described [22].
2.16. Statistical analysis
Statistical analyses for genetic studies were performed in R [23] and
SAS 9.2 (SAS Institute, Cary, NC). Hardy–Weinberg equilibrium and
pairwise linkage disequilibrium coefﬁcients expressed as r2 were
calculated with HaploView 3.32 [24]. All skewed variables were log
transformed to obtain a normal distribution before statistical computa-
tions and signiﬁcance testing. The effect size of genotypes was estimat-
ed from β coefﬁcients per minor allele tested under an additive genetic
model, using linear regression models for continuous and logistic
regression models for dichotomized dependent variables, adjusting for
age, gender, myocardial infarction, and ejection fraction. Groups werecompared by two-tailed t test. An additive linear model was used to
estimate the fold-change in gene expression per minor allele. Values
b1 indicate decreased expression with the minor allele of the SNP
rs884164. Formouse studies, data are shown asmean± SEM.Measure-
ments were compared with the two-tailed t test or Mann–Whitney
rank-sum test.3. Results
3.1. Reduced myocardial triglycerides in Plin5−/− hearts
To investigate the role of Plin5 in myocardial lipid metabolism and
heart function, we generated Plin5−/− mice (Fig. S1) and assessed
their cardiac physiology and biochemistry. Plin5−/− mice did not
express Plin5 in the heart (Fig. 1A). Bodyweight and plasma cholesterol
and triglyceride levels did not differ between 3-month-old WT and
Plin5−/−mice on a chow diet (data not shown).
To determine whether Plin5 deﬁciency affects cardiac lipid
accumulation, we used lipidomics to analyze heart tissue from WT
and Plin5−/− mice. Triglyceride levels in the heart were markedly
lower in Plin5−/−mice than in WT mice (Fig. 1B). Diacylglycerol levels
were also lower in Plin5−/− hearts, but surprisingly there were no
differences in other analyzed glycerolipid species or membrane lipids
(Fig. 1B). In addition, Plin5−/− hearts contained a higher percentage of
triglycerides with medium-chain fatty acids and a lower percentage of
triglycerides with long-chain and very-long-chain fatty acids (Fig. S2).
As shown by electron microscopy of left ventricular sections, lipid
droplets were large and located close to mitochondria in WT hearts,
but were smaller, tended to be less numerous, and were not closely
associated with mitochondria in Plin5−/− hearts (Fig. 1C–F). These
observations indicate that Plin5 stabilizes lipid droplets, thus allowing
increased storage of triglycerides, and facilitates their association with
mitochondria in vivo.3.2. Reduced fatty acid uptake in Plin5−/− hearts
Plin5 has previously been suggested to play a role as a lipolytic
barrier on the lipid droplet surface, [25] protecting lipids from hydroly-
sis. We next investigated whether Plin5 deﬁciency also resulted in
altered fatty acid uptake. Importantly, we found that fatty acid uptake
was markedly decreased in Plin5−/− hearts (Fig. 2A). After adjusting
for the reduced uptake of fatty acids in Plin5−/− hearts, the incorpora-
tion of fatty acids into triglycerides was reduced (Fig. 2B), there was
no difference in the incorporation of fatty acids into phosphatidic acid
and diglycerides (Fig. 2C), and the incorporation of fatty acids into phos-
pholipids was markedly increased (Fig. 2D) in Plin5−/− compared with
WT hearts. The altered glycerolipid pathway in the Plin5−/− hearts is
shown schematically in Fig. 2E.
These data indicate the Plin5−/− heart compensates for its reduced
capacity to store triglycerides by decreasing fatty acid uptake and
suggest that the incorporation of fatty acids in the glycerolipid pathway
is shifted from triglycerides to phospholipids, thus maintaining mem-
brane homeostasis.3.3. Increased glucose uptake in Plin5−/− hearts
Given the marked reductions in triglyceride levels and fatty acid
uptake in Plin5−/− hearts, we tested whether these hearts use glucose
as an energy source instead of lipids. As shown by 3H-2-deoxyglucose
injections, glucose uptake was 2-fold higher in Plin5−/− than in WT
hearts (Fig. 3). Collectively, our results suggest that Plin5−/− mice
undergo a metabolic shift leading to reduced fatty acid uptake and
increased glucose uptake to maintain their energy metabolism under
normal conditions.
Fig. 1. Reduced myocardial triglycerides in Plin5−/−mice. (A) Immunoblot of Plin5 protein in hearts from WT and Plin5−/− mice. (B) Lipid content in heart of 12-week-old WT and
Plin5−/− mice on a chow diet. Glycero- and sphingolipids were measured with high-performance liquid chromatography and mass spectrometry (n = 5–8). (C) Representative
electron microscopy images of WT and Plin5−/− hearts. Lipid droplets are marked with a white arrow and mitochondria are marked with a black arrow. (D) Lipid droplet size
measured as the cross-sectional area of lipid droplets in WT and Plin5−/− hearts. 40 lipid droplets per mouse were averaged. (E) Number of lipid droplets per image in WT and
Plin5−/− hearts, quantiﬁed in 10 images per mouse. (F) Distance between the lipid droplet and the closest mitochondrion (D–F; n = 3 per genotype) Values are mean ± SEM.
*P b 0.05; **P b 0.01; ***P b 0.001 vsWT. CE, cholesterol ester; TAG, triglyceride; SM, sphingomyelin, CER, ceramide; DAG, diacylglycerol; FC, free cholesterol; PC, phosphatidylcholine;
PE phosphatidylethanolamine; LD, lipid droplet.
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Next, we examined the effect of Plin5 deﬁciency following
myocardial ischemia in mice. We observed signiﬁcantly lower levels of
C2 and C4 acylcarnitines after a myocardial infarction (induced by liga-
tion of the left anterior descending artery) in Plin5−/− hearts compared
with WT hearts (Fig. 4A), indicating that fatty acid oxidation is down-
regulated in Plin5−/− hearts. In addition, we found that accumulation
of glycogen was markedly increased in the septum of WT but not
Plin5−/− hearts after a myocardial infarction compared with baseline
(Fig. 4B and C), suggesting that Plin5−/− hearts utilize all available
glucose because of their reduced triglyceride content. Thus, our results
indicate that Plin5−/− hearts display dysregulated metabolism follow-
ing a myocardial infarction.3.5. Impaired cardiac function and reduced survival in Plin5−/−mice after
myocardial stress
We next investigated whether the dysregulated metabolism
in Plin5−/− hearts was paralleled by impaired heart function and
survival after myocardial stress in mice. Under baseline conditions,
Plin5−/−mice displayed nodifferences in heart dimension or stroke vol-
ume and amodest reduction in ejection fraction (Fig. 5A and B), indicat-
ing that Plin5−/− mice and WT mice have similar heart function.
However, when we used the β-adrenergic agonist dobutamine to max-
imize the heart's capacity, we observed dramatic differences in diastolic
dimensions and stroke volume betweenWT and Plin5−/−mice (Fig. 5C
and Table S3). Importantly, we also showed that Plin5−/−mice had re-
duced survival after an induced myocardial infarction (Fig. 5D).
Fig. 2. Reduced fatty acid uptake and shifted incorporation of fatty acids into phospholipids in Plin5−/− hearts. (A) [3H]-palmitate uptake inWT and Plin5−/− hearts (n= 4–7). (B) [3H]-
palmitate incorporation into triglycerides adjusted for fatty acid uptake (n= 4–7). (C) [3H]-palmitate incorporation into diglycerides and phosphatidic acid adjusted for fatty acid uptake
(n = 4–7). (D) [3H]-palmitate incorporation into phosphatidylcholine and phosphatidylethanolamine adjusted for fatty acid uptake (n = 4–7). (E) Schematic overview of the effect of
Plin5 deﬁciency on the cardiac glycerolipid synthesis after corrected for fatty acid uptake. The ﬂux of fatty acid was shifted from incorporation into triglycerides towards incorporation
into phospholipids. *P b 0.05; **P b 0.01; ***P b 0.001 vsWT. PA, phosphatidic acid; PL phospholipids.
Fig. 3. Increased glucose uptake Plin5−/− hearts. (A) Basal glucose uptake in heart of WT
and Plin5−/−mice on a chow diet was assessed after a single injection of 2-deoxyglucose
(n = 10–12). *P b 0.05; **P b 0.01 vsWT.
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from three days after induced ischemia (Fig. 5D).
Together, these data indicate that, although Plin5−/−mice maintain
relatively normal heart function under baseline conditions, cardiac
function is reduced during stress and mortality is increased following
myocardial ischemia.
3.6. Genetic variation in PLIN5 is associated with impaired cardiac function
after myocardial ischemia in humans
To elucidate if Plin5 is relevant to myocardial physiology in humans,
especially in the setting ofmyocardial ischemia, we investigatedwheth-
er genetic variation in PLIN5 is associated with cardiac dysfunction after
myocardial ischemia. 466 patients with suspected coronary artery
disease underwent myocardial perfusion scintigraphy examinations
(Table S1) and were genotyped for four single nucleotide polymor-
phisms (SNPs) across PLIN5 (Fig. 1). All SNPs had a minor allele
frequency N5% and were in Hardy–Weinberg equilibrium without
linkage disequilibrium (Table S2). Importantly, PLIN5 rs884164
was consistently and signiﬁcantly associated with several variables
(Table 1). The minor rs884164 allele was signiﬁcantly associated with
a higher wall motion score, reﬂecting reduced heart muscle motion
due to myocardial ischemia. Furthermore, a larger reversibility mass
(a signiﬁcant predictor of major adverse cardiovascular events [26]),
was also signiﬁcantly associated with the minor rs884164 allele.
Next, we assessed the summed stress score (SSS), which indicates
perfusion abnormalities during stress, reﬂecting both myocardial
ischemia and infarction. Since an SSS N8 is associated with higher mor-
tality from cardiac events [27], we used this cut-off to dichotomize the
participants. The minor rs884164 allele was associated with an SSS N8(β±se: 0.862±0.374, P=0.02), which suggests that patients carrying
this allele are at higher risk of cardiovascular morbidity and mortality
after myocardial ischemia.
SNP rs884164 is located in an intergenic region at the 3′ end of
PLIN5 and 5′ of PLIN4. These noncoding parts of the genome are believed
to be vital for correct spatial and temporal gene expression [28]. We an-
alyzed the mRNA expression of PLIN5 and PLIN4 in human hearts (n =
127) and found that PLIN5 expression was reduced if the subject
had the minor rs884164 allele. The per-allele effect on expression was
0.78 (95% conﬁdence interval (CI) 0.61–1.00; P = 0.04; values below
1 indicate decreased expression with the minor rs884164 allele),
revealing that this SNP affects PLIN5 expression. rs884164 did not
Fig. 4. Reduced substrate availability in Plin5−/− hearts. (A) Acyl carnitine species, markers of substrate oxidation, in hearts of WT and Plin5−/−mice measured with mass spectrometry
(n = 5–8). (B) Representative images showing glycogen accumulation in WT and Plin5−/− hearts at baseline and after an induced myocardial infarction (MI). (C) Quantiﬁcation of
glycogen in the interventricular septal wall (n = 4–6). Values are mean ± SEM. *P b 0.05; **P b 0.01 vsWT.
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P= 0.44).
Thus, genetic variation in PLIN5 associates with impaired cardiac
function after myocardial ischemia in humans, indicating that PLIN5
function is relevant to human cardiac physiology.
4. Discussion
In this study, we investigated Plin5 and its role in cardiac dysfunc-
tion and outcome after myocardial ischemia. In mice, Plin5 deﬁciency
resulted in a dramatic reduction in myocardial lipid accumulation.
Under normal conditions, the energy balance in Plin5−/− hearts was
maintained by increasing glucose uptake and utilization, allowing a
close to normal heart function. However, Plin5 deﬁciency in the ische-
mic heart resulted in dysregulated metabolism, which was accompa-
nied by markedly reduced heart function and decreased survival. In
humans, we found that the common SNP rs884164 alters cardiac
expression of PLIN5 and associates with several variables linked to
reduced heart function and adverse outcome aftermyocardial ischemia.
Thus, our results suggest that Plin5 plays a role in cardioprotection dur-
ing myocardial ischemia.
Our observation that hearts of Plin5−/− mice had markedly lower
triglyceride levels and fewer lipid droplets is in agreement with results
from a previous mouse model of Plin5 deﬁciency [16]. We also showed
that the distance between lipid droplets and mitochondria was greater
in Plin5−/− hearts than in WT hearts, suggesting dysfunctional lipid
utilization. Previous studies in cell lines showed that Plin5 protects
lipid droplets from lipolysis but paradoxically also increases fatty acid
oxidation [31,32], which could potentially be explained by Plin5
regulating the transfer of fatty acids from lipid droplets tomitochondria.
Importantly, our data suggest that Plin5−/− hearts compensate for re-
duced triglyceride storage capacity by markedly decreasing fatty aciduptake and incorporation into triglycerides. Furthermore, we found
that the incorporation of fatty acids into phospholipids was increased
in Plin5−/− hearts after accounting for the reduced fatty acid uptake.
Maintaining the homeostasis of cellular membranes (e.g. the endoplas-
mic reticulum) is crucial for many cellular functions including protein
folding [33]. Similar changes in fatty acid ﬂux into phospholipids
rather than storage of triglycerides have previously been shown in
Scd1-deﬁcient mice [34]. Taken together, our data suggest that the
decreased triglyceride levels in Plin5−/− hearts are not explained by
increased fatty acid oxidation but instead by decreased fatty acid
uptake and a shift of fatty acid incorporation from triglycerides to
phospholipids.
Because glucose uptake and utilization were higher in Plin5−/−
hearts compared with WT hearts, we propose that the Plin5−/− mice
maintain nearly normal heart function under baseline conditions by
increasing glucose utilization. During stress and conditions of reduced
oxygen supply, it is well known that glucose uptake is increased in the
heart [35,36]. The increased glucose uptake is seen even in regions
remote from the ischemic area, and glucose that is not consumed can
be stored as glycogen for later use [35,36]. We observed amarked accu-
mulation of glycogen in the interventricular wall in WT mice following
an induced myocardial infarction, suggesting that energy production
through lipid oxidation is maintained in this region under ischemic
conditions, and thus the heart does not need to use large amounts of
glucose. By contrast, despite the higher level of glucose uptake in
Plin5−/− hearts under baseline conditions, Plin5−/− hearts were not
capable of accumulating glycogen in the interventricular wall following
a myocardial infarction, indicating that they instead utilized all the
glucose in an attempt to sustain energy production. However, this
increased glucose utilization in Plin5−/− hearts did not appear to be suf-
ﬁcient to maintain function as survival was reduced in Plin5−/− mice
after a myocardial infarction.
Fig. 5. Impaired cardiac function and reduced survival in Plin5−/−mice after myocardial stress. (A) Representative images of the end-diastolic and end-systolic phase of WT and Plin5−/−
hearts under baseline conditions. (B) Baseline left ventricular diastolic volume, stroke volume and ejection fraction inWT and Plin5−/−mice assessedwith echocardiography (n=13–14).
(C) Change relative to baseline in left ventricular diastolic volume, stroke volume and ejection fraction inWT and Plin5−/−mice after stimulationwith dobutamine (n=5). (D) Survival of
WT and Plin5−/−mice after an induced myocardial infarction (n = 11). Values are mean ± SEM. *P b 0.05 vsWT.
452 C. Drevinge et al. / International Journal of Cardiology 219 (2016) 446–454Our ﬁndings suggest that the presence of Plin5 affects metabolic
ﬂexibility of the heart. In agreement with a role for Plin5 in metabolic
ﬂexibility, a recent study in mice with Plin5 overexpression in cardiac
muscle showed that Plin5 regulation of lipolysis is abolished by protein
kinase A (PKA) [37], suggesting that epinephrine could activate PKA to
increase the release of fatty acids from lipid droplets under conditions
of stress and high workload. Since the total energy pool can turn over
rapidly at high workload, even modest alterations in myocardial lipid
metabolism may have a substantial effect on contractile function. We
therefore speculate that Plin5 is important for metabolic ﬂexibility
during conditions of myocardial stress by regulating the release of
fatty acids from the triglyceride storage pool for transfer to the mito-
chondria and fatty acid oxidation.
Earlier reports have shown that genetic variations in perilipins 1 and
4 are associated with human disease [29], and here we found that
patients carrying the SNP rs884164, aminor allele of PLIN5, are at higher
risk of cardiovascular morbidity after myocardial ischemic events.
rs884164 is located 3′ of the coding region of PLIN5 and 5′ of PLIN4 on
chromosome 19, a part of the genome believed to be vital for correctspatial and temporal gene expression.28 We found that the minor allele
of the rs884164 was associated with reduced expression of PLIN5 in
human hearts. A meta-analysis has shown that rs884164 is associated
with high plasma levels of polyunsaturated fatty acid and triglycerides
[30], and we observed that patients with rs884164 responded worse
to ischemia as indicated by a larger reversibility mass and wall motion
abnormalities. Thus, a genetic variation that reduces cardiac PLIN5
expression is associated with reduced cardiac function after myocardial
ischemia in humans.
There are limitations to this study. The experimentswere performed
in amouse model withwhole body Plin5 deﬁciency. Therefore, contrib-
uting effects of other cell types and organs on cardiac metabolism
cannot be excluded. However, Plin5 is not ubiquitously expressed, but
rather expressed in oxidative tissues such as heart, liver and skeletal
muscle. Furthermore, cell types in the heart other than cardiomyocytes,
e.g. endothelial cells and ﬁbroblasts, do not normally express high levels
of Plin5. Thus, knockout of Plin5 would not substantially affect the
function of these cells. In accordance with this, we observed large lipid
droplets in endothelial cells in EM images of Plin5−/− hearts in contrast
Table 1
Association of PLIN5 polymorphisms with myocardial perfusion imaging.
Variable
rs884164 rs1062223 rs1610090 rs11085080
β± se P β± se P β± se P β± se P
Infarct score 0.944 ± 0.463 0.042 0.081 ± 0.348 0.815 −0.073 ± 0.485 0.880 0.192 ± 0.658 0.771
Infarct area 1.021 ± 0.436 0.019 −0.146 ± 0.340 0.668 −0.230 ± 0.479 0.631 0.315 ± 0.614 0.608
Ischemia score 0.414 ± 0.296 0.161 0.004 ± 0.207 0.985 0.094 ± 0.265 0.723 0.390 ± 0.341 0.254
Ischemia area 0.478 ± 0.295 0.105 0.039 ± 0.207 0.849 0.053 ± 0.267 0.842 0.317 ± 0.345 0.358
Ischemia severity 0.499 ± 0.295 0.090 −0.035 ± 0.208 0.866 0.130 ± 0.264 0.622 0.375 ± 0.343 0.273
SSSa 0.862 ± 0.374 0.021 −0.538 ± 0.279 0.054 −0.190 ± 0.356 0.593 0.119 ± 0.424 0.779
Wall motion scoreb 1.066 ± 0.441 0.016 −0.437 ± 0.375 0.244 −0.668 ± 0.541 0.217 0.356 ± 0.606 0.557
Reversible ischemiac 1.163 ± 0.502 0.020 0.013 ± 0.427 0.976 −0.245 ± 0.613 0.690 1.125 ± 0.574 0.050
The beta refers to the effect of each additional copy of theminor allele with corresponding standard errors and P values adjusted for age, gender, prior myocardial infarction, and ejection
fraction.
Bold numbers indicate signiﬁcance at P b 0.05.
a SSS, summed stress score dichotomized using a score N8 as cut-off.
b Wall motion score dichotomized using a score ≥2 as cut-off.
c Reversible ischemia, the reversibility mass percent of myocardium dichotomized using a score ≥10% as cut-off.
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potentially confounding effect is that insulin sensitivity and/or levels
of circulating lipids may be altered due to the absence of Plin5 in non-
cardiac tissue [38]. However, we used young Plin5−/−mice fed a chow
diet for our experiments. These mice did not differ in weight compared
with WT mice and plasma levels of triglycerides, cholesterol, glucose
and insulin were similar between the genotypes. In addition, no differ-
ences in circulating triglycerides, fatty acids or insulin were found be-
tween WT and Plin5−/− mice following myocardial ischemia. Thus,
our results describing the effect of Plin5 on heart function and cardiac
lipidmetabolismare not likely due to systemic effects of Plin5 knockout.
In conclusion, our ﬁndings elucidate the role of Plin5 in cardiac lipid
metabolism and identify Plin5 as a potential cardioprotector following
myocardial ischemia.
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